Maat Pharma S.A.C.A (MAAT) | Stock Overview & Key Data
Maat Pharma S.A.C.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €14.40 on November 8, 2021
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maat Pharma S.A.C.A
MAAT
|
99.87M Small-cap | 4.27% | -50.17% | -51.97% | -51.97% | -51.97% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -36.61% | -28.82% | -25.31% | -26.24% | -38.04% | 2,047.73% | 517.65% | 305.72% | 1,019.45% | 447.83% | 447.83% |
|
Nanobiotix
NANO
|
1.39B Large-cap | -12.69% | 13.65% | 14.38% | 69.14% | 58.63% | 827.52% | 612.13% | 134.60% | 81.06% | 449.03% | 449.03% |
|
Abionyx Pharma S.A
ABNX
|
128.36M Small-cap | -8.55% | -18.48% | -12.03% | -26.26% | -28.90% | 120.00% | 121.71% | 123.44% | -65.29% | -76.80% | -76.80% |
| 108.28M Small-cap | 0.00% | 23.20% | 42.59% | 42.59% | 42.59% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | |
|
Adocia S.A
ADOC
|
90.92M Small-cap | -16.80% | -12.18% | -33.92% | -48.11% | -38.93% | 33.97% | 24.49% | -48.16% | -91.56% | -47.55% | -47.55% |
Ownership & Short Interest
Calculate Your Maat Pharma S.A.C.A Investment Returns
Long-Term Investment Performance Analysis
Maat Pharma S.A.C.A stock price in Mar 2026 was €6.50, A €1,000.00 lump sum investment in Maat Pharma S.A.C.A made 0 years ago would be worth approximately €450.77 today, representing a negative return of -54.92%.
2 Months Investment Scenario (Mar 2026 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is MAAT's 52-week high and low?
- In the last 52 weeks, Maat Pharma S.A.C.A reached a high of €8.62 (on January 29, 2026) and a low of €2.60 (on May 21, 2026).
- What is the market cap and P/E ratio for MAAT?
- Curious about Maat Pharma S.A.C.A's size and valuation? Its market capitalization stands at 99.87M. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.47, and the forward P/E (looking ahead) is -5.15.
- Does MAAT pay dividends? If so, what's the yield?
- As for dividends, Maat Pharma S.A.C.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Maat Pharma S.A.C.A's main competitors or similar companies to consider before investing?
When looking at Maat Pharma S.A.C.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 2,047.73% 517.65% Nanobiotix
NANO1.39B Healthcare Biotechnology 827.52% 612.13% Abionyx Pharma S.A
ABNX128.36M Healthcare Biotechnology 120.00% 121.71% Innate Pharma S.A
IPH108.28M Healthcare Biotechnology 46.36% 46.36% Adocia S.A
ADOC90.92M Healthcare Biotechnology 33.97% 24.49% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Maat Pharma S.A.C.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Maat Pharma S.A.C.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -511.92%, the Debt to Equity ratio from the most recent quarter is 969.43, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for MAAT?
- Looking at Maat Pharma S.A.C.A's growth, its revenue over the trailing twelve months (TTM) was €5M. Compared to the same quarter last year (YoY), quarterly revenue grew by 40.30%, and quarterly earnings saw a YoY growth of N/A.
- How much of MAAT stock is held by insiders and institutions?
- Wondering who owns Maat Pharma S.A.C.A stock? Company insiders (like executives and directors) hold about 22.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 47.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.